144 related articles for article (PubMed ID: 18066144)
1. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products.
Budzinski JW; Trudeau VL; Drouin CE; Panahi M; Arnason JT; Foster BC
Can J Physiol Pharmacol; 2007 Sep; 85(9):966-78. PubMed ID: 18066144
[TBL] [Abstract][Full Text] [Related]
2. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
Eagling VA; Profit L; Back DJ
Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
[TBL] [Abstract][Full Text] [Related]
4. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents.
Etheridge AS; Black SR; Patel PR; So J; Mathews JM
Planta Med; 2007 Jul; 73(8):731-41. PubMed ID: 17611934
[TBL] [Abstract][Full Text] [Related]
5. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?
Gutmann H; Poller B; Büter KB; Pfrunder A; Schaffner W; Drewe J
Planta Med; 2006 Jun; 72(8):685-90. PubMed ID: 16755466
[TBL] [Abstract][Full Text] [Related]
6. An ex vivo approach to botanical-drug interactions: a proof of concept study.
Wang X; Zhu HJ; Munoz J; Gurley BJ; Markowitz JS
J Ethnopharmacol; 2015 Apr; 163():149-56. PubMed ID: 25623616
[TBL] [Abstract][Full Text] [Related]
7. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
8. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions.
Hermann R; von Richter O
Planta Med; 2012 Sep; 78(13):1458-77. PubMed ID: 22855269
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification.
Chan LM; Cooper AE; Dudley AL; Ford D; Hirst BH
J Drug Target; 2004; 12(7):405-13. PubMed ID: 15621665
[TBL] [Abstract][Full Text] [Related]
10. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
van Erp NP; Baker SD; Zhao M; Rudek MA; Guchelaar HJ; Nortier JW; Sparreboom A; Gelderblom H
Clin Cancer Res; 2005 Nov; 11(21):7800-6. PubMed ID: 16278402
[TBL] [Abstract][Full Text] [Related]
11. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir.
Mouly SJ; Paine MF; Watkins PB
J Pharmacol Exp Ther; 2004 Mar; 308(3):941-8. PubMed ID: 14718607
[TBL] [Abstract][Full Text] [Related]
12. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
13. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
Berginc K; Trdan T; Trontelj J; Kristl A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
[TBL] [Abstract][Full Text] [Related]
14. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.
Patel J; Hussain A; Pal D; Mitra AK
Am J Ther; 2004; 11(2):114-23. PubMed ID: 14999363
[TBL] [Abstract][Full Text] [Related]
15. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures.
Budzinski JW; Foster BC; Vandenhoek S; Arnason JT
Phytomedicine; 2000 Jul; 7(4):273-82. PubMed ID: 10969720
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the coordinated functional activities of cytochrome P450 3A4 and P-glycoprotein in limiting the absorption of xenobiotics in Caco-2 cells.
Tran CD; Timmins P; Conway BR; Irwin WJ
J Pharm Sci; 2002 Jan; 91(1):117-28. PubMed ID: 11782903
[TBL] [Abstract][Full Text] [Related]
18. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4.
Takanaga H; Ohnishi A; Yamada S; Matsuo H; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
J Pharmacol Exp Ther; 2000 Apr; 293(1):230-6. PubMed ID: 10734174
[TBL] [Abstract][Full Text] [Related]
19. CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies.
Engman HA; Lennernäs H; Taipalensuu J; Otter C; Leidvik B; Artursson P
J Pharm Sci; 2001 Nov; 90(11):1736-51. PubMed ID: 11745731
[TBL] [Abstract][Full Text] [Related]
20. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans.
Hajda J; Rentsch KM; Gubler C; Steinert H; Stieger B; Fattinger K
Eur J Pharm Sci; 2010 Dec; 41(5):729-35. PubMed ID: 20933082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]